{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:15:49Z","timestamp":1789578949023,"version":"build-2803163510"},"reference-count":18,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T00:00:00Z","timestamp":1555977600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosmedicine.org"],"crossmark-restriction":false},"short-container-title":["PLoS Med"],"DOI":"10.1371\/journal.pmed.1002787","type":"journal-article","created":{"date-parts":[[2019,4,23]],"date-time":"2019-04-23T17:25:02Z","timestamp":1556040302000},"page":"e1002787","update-policy":"https:\/\/doi.org\/10.1371\/journal.pmed.corrections_policy","source":"Crossref","is-referenced-by-count":41,"title":["Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4269-3699","authenticated-orcid":true,"given":"Gavin J.","family":"Churchyard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sue","family":"Swindells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2019,4,23]]},"reference":[{"key":"ref1","unstructured":"Global Tuberculosis Report 2018. Geneva: World Health Organization, Contract No.: WHO\/CDS\/TB\/2018.20."},{"issue":"10","key":"ref2","doi-asserted-by":"crossref","first-page":"e1002152","DOI":"10.1371\/journal.pmed.1002152","article-title":"The Global Burden of Latent Tuberculosis Infection: A Re-estimation Using Mathematical Modelling","volume":"13","author":"RM Houben","year":"2016","journal-title":"PLoS Med"},{"key":"ref3","first-page":"28","article-title":"Controlled chemoprophylaxis trials in tuberculosis. A general review","volume":"26","author":"SH Ferebee","year":"1970","journal-title":"Bibl Tuberc"},{"issue":"11","key":"ref4","doi-asserted-by":"crossref","first-page":"e1080","DOI":"10.1016\/S2214-109X(17)30372-8","article-title":"Effect of isoniazid preventive therapy on risk of death in west African, HIV-infected adults with high CD4 cell counts: long-term follow-up of the Temprano ANRS 12136 trial","volume":"5","author":"A Badje","year":"2017","journal-title":"Lancet Glob Health"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1016\/S0140-6736(11)60204-3","article-title":"6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial","volume":"377","author":"T Samandari","year":"2011","journal-title":"Lancet"},{"key":"ref6","unstructured":"Seddon JA, Fred D, Amanullah F, Schaaf HS, Starke JR, Keshavjee S, et al. Post-exposure management of multidrug-resistant tuberculosis contacts: evidence based recommendations. Dubai, United Arab Emirates: Harvard Medical School Center for Global Health Delivery-Dubai, 2015."},{"issue":"10","key":"ref7","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1473-3099(13)70187-7","article-title":"Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial","volume":"13","author":"B Durovni","year":"2013","journal-title":"Lancet Infect Dis"},{"issue":"10010","key":"ref8","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/S0140-6736(15)00323-2","article-title":"Controlling the seedbeds of tuberculosis: diagnosis and treatment of tuberculosis infection","volume":"386","author":"MX Rangaka","year":"2015","journal-title":"Lancet"},{"key":"ref9","unstructured":"Latent tuberculosis infection: updated and consolidated guidelines for programmatic management. Geneva: World Health Organization, 2018. Contract No.: WHO\/CDS\/TB\/2018.4."},{"issue":"6","key":"ref10","first-page":"991","article-title":"Isoniazid-related hepatitis: a U.S. Public Health Service cooperative surveillance study","volume":"117","author":"DE Kopanoff","year":"1978","journal-title":"Am Rev Respir Dis"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"744","DOI":"10.3201\/eid1205.050681","article-title":"Isoniazid preventive therapy and risk for resistant tuberculosis","volume":"12","author":"ME Balcells","year":"2006","journal-title":"Emerg Infect Dis"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1056\/NEJMoa1214289","article-title":"A trial of mass isoniazid preventive therapy for tuberculosis control","volume":"370","author":"GJ Churchyard","year":"2014","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis","volume":"16","author":"H Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis","volume":"380","author":"S Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1093\/cid\/civ464","article-title":"Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention","volume":"61","author":"AT Podany","year":"2015","journal-title":"Clin Infect Dis"},{"key":"ref16","unstructured":"Dooley EL, Churchyard G, Savik RM, Gupte A, Markzinke MA, Zhang N, et al. Safety & PK of weekly rifapentine\/isoniazid (3HP) in adults with HIV on dolutegravir. Conference on Retroviruses and Opportunistic Infections. 2019; Seattle, United States."},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1093\/cid\/ciy230","article-title":"Cost-effectiveness of Preventive Therapy for Tuberculosis With Isoniazid and Rifapentine Versus Isoniazid Alone in High-Burden Settings","volume":"67","author":"KT Johnson","year":"2018","journal-title":"Clin Infect Dis"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"e806","DOI":"10.1016\/S2214-109X(16)30199-1","article-title":"Feasibility of achieving the 2025 WHO global tuberculosis targets in South Africa, China, and India: a combined analysis of 11 mathematical models","volume":"4","author":"R Houben","year":"2016","journal-title":"Lancet Glob Health"}],"container-title":["PLOS Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pmed.1002787","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,9]],"date-time":"2020-05-09T14:09:08Z","timestamp":1589033348000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pmed.1002787"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,4,23]]},"references-count":18,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,23]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pmed.1002787","relation":{},"ISSN":["1549-1676"],"issn-type":[{"value":"1549-1676","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,23]]}}}